{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:07:35Z","timestamp":1790168855829,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T00:00:00Z","timestamp":1468368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00228-016-2092-3","type":"journal-article","created":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T23:47:31Z","timestamp":1468453651000},"page":"1245-1254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders\u2014a pharmacoepidemiological study and clinical implications"],"prefix":"10.1007","volume":"72","author":[{"given":"Arton","family":"Baftiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Johannessen Landmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Rudberg","family":"Rusten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje Andrea","family":"Feet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein I.","family":"Johannessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l G.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"2092_CR1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1600-0404.2006.00639.x","volume":"113","author":"I Tsiropoulos","year":"2006","unstructured":"Tsiropoulos I, Gichangi A, Andersen M, Bjerrum L, Gaist D, Hallas J (2006) Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand 113:405\u2013411","journal-title":"Acta Neurol Scand"},{"key":"2092_CR2","first-page":"1317","volume":"14","author":"R Savica","year":"2007","unstructured":"Savica R, Beghi E, Mazzaglia G, Innocenti F, Brignoli O, Cricelli C, Caputi AP, Musolino R, Spina E, Trifir\u00f2 G (2007) Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. Eur J Neurol Off J Eur Fed Neurol Soc 14:1317\u20131321","journal-title":"Eur J Neurol Off J Eur Fed Neurol Soc"},{"key":"2092_CR3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.07.005","volume":"87","author":"C Johannessen Landmark","year":"2009","unstructured":"Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI (2009) Antiepileptic drugs in epilepsy and other disorders\u2014a population-based study of prescriptions. Epilepsy Res 87:31\u201339","journal-title":"Epilepsy Res"},{"key":"2092_CR4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eplepsyres.2011.02.012","volume":"95","author":"CJ Landmark","year":"2011","unstructured":"Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI (2011) Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 95:51\u201359","journal-title":"Epilepsy Res"},{"key":"2092_CR5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2125.2010.03619.x","volume":"70","author":"A Oteri","year":"2010","unstructured":"Oteri A, Trifiro G, Gagliostro MS, Tari DU, Moretti S, Bramanti P, Spina E, Caputi AP, Arcoraci V (2010) Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07. Br J Clin Pharmacol 70:514\u2013522","journal-title":"Br J Clin Pharmacol"},{"key":"2092_CR6","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bcp.12577","volume":"79","author":"D Italiano","year":"2015","unstructured":"Italiano D, Capuano A, Alibrandi A, Ferrara R, Cannata A, Trifiro G, Sultana J, Ferrajolo C, Tari M, Tari DU, Perrotta M, Pagliaro C, Rafaniello C, Spina E, Arcoraci V (2015) Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011. Br J Clin Pharmacol 79:1010\u20131019","journal-title":"Br J Clin Pharmacol"},{"key":"2092_CR7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.addr.2011.10.003","volume":"64","author":"C Johannessen Landmark","year":"2012","unstructured":"Johannessen Landmark C, Johannessen SI, Tomson T (2012) Host factors affecting antiepileptic drug delivery-pharmacokinetic variability. Adv Drug Deliv Rev 64:896\u2013910","journal-title":"Adv Drug Deliv Rev"},{"key":"2092_CR8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00023210-200822010-00003","volume":"22","author":"C Johannessen Landmark","year":"2008","unstructured":"Johannessen Landmark C (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22:27\u201347","journal-title":"CNS Drugs"},{"key":"2092_CR9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pds.2269","volume":"21","author":"CJ Landmark","year":"2012","unstructured":"Landmark CJ, Johannessen SI (2012) Safety aspects of antiepileptic drugs\u2014focus on pharmacovigilance. Pharmacoepidemiol Drug Saf 21:11\u201320","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2092_CR10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00228-011-1088-2","volume":"68","author":"Y Takahashi","year":"2012","unstructured":"Takahashi Y, Nishida Y, Asai S (2012) Utilization of health care databases for pharmacoepidemiology. Eur J Clin Pharmacol 68:123\u2013129","journal-title":"Eur J Clin Pharmacol"},{"key":"2092_CR11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2042098611404920","volume":"2","author":"L Wise","year":"2011","unstructured":"Wise L (2011) Risks and benefits of (pharmaco)epidemiology. Ther Adv Drug Saf 2:95\u2013102","journal-title":"Ther Adv Drug Saf"},{"key":"2092_CR12","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1007\/s00415-012-6509-3","volume":"259","author":"HM Hamer","year":"2012","unstructured":"Hamer HM, Dodel R, Strzelczyk A, Balzer-Geldsetzer M, Reese JP, Schoffski O, Graf W, Schwab S, Knake S, Oertel WH, Rosenow F, Kostev K (2012) Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany\u2014a nationwide population-based study in children and adults. J Neurol 259:2376\u20132384","journal-title":"J Neurol"},{"key":"2092_CR13","unstructured":"WHO. (2002) The importance of pharmacovigilance. Safety Monitoring of Medicinal Products. World Health Organization 2002."},{"key":"2092_CR14","unstructured":"WHO Collaboration Center. Available at http:\/\/www.whocc.no ."},{"key":"2092_CR15","unstructured":"The Norwegian Institute of Public Health, The National Prescription Database (NorPD). Available at: http:\/\/www.reseptregisteret.no ."},{"key":"2092_CR16","first-page":"129","volume":"18","author":"K Furu","year":"2008","unstructured":"Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD)\u2014new opportunities for research in pharmacoepidemiology in Norway. Nor Epidemiol 18:129\u2013136","journal-title":"Nor Epidemiol"},{"key":"2092_CR17","unstructured":"ICD-10 classification system. Available at: http:\/\/www.who.int\/classifications\/icd\/en\/ ."},{"key":"2092_CR18","unstructured":"ICPC-2 classification system. Available at: https:\/\/helsedirektoratet.no\/helsefaglige-kodeverk\/icpc-2-den-internasjonale-klassifikasjonen-for-primerhelsetjenesten . [Norwegian]"},{"key":"2092_CR19","unstructured":"Statistics Norway. Available at: http:\/\/www.ssb.no ."},{"key":"2092_CR20","unstructured":"The Norwegian Medicines Agency. Reimbursement status for pregabalin. Available at: http:\/\/www.legemiddelverket.no ."},{"key":"2092_CR21","unstructured":"The Norwegian Medicines Agency. Reimbursement status for gabapentin. Available at: http:\/\/www.legemiddelverket.no ."},{"key":"2092_CR22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","volume":"54","author":"T Glauser","year":"2013","unstructured":"Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, Mattson R, French JA, Perucca E, Tomson T (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54:551\u2013563","journal-title":"Epilepsia"},{"key":"2092_CR23","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00228-010-0861-y","volume":"66","author":"M Karouni","year":"2010","unstructured":"Karouni M, Arulthas S, Larsson PG, Rytter E, Johannessen SI, Landmark CJ (2010) Psychiatric comorbidity in patients with epilepsy: a population-based study. Eur J Clin Pharmacol 66:1151\u20131160","journal-title":"Eur J Clin Pharmacol"},{"key":"2092_CR24","doi-asserted-by":"crossref","unstructured":"Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. The Primary Care Companion for CNS Disorders 2011;13","DOI":"10.4088\/PCC.10r01097"},{"key":"2092_CR25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jad.2009.01.006","volume":"117","author":"JG Bramness","year":"2009","unstructured":"Bramness JG, Groholt B, Engeland A, Furu K (2009) The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007\u2014a prescription database study. J Affect Disord 117:208\u2013211","journal-title":"J Affect Disord"},{"key":"2092_CR26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pediatrneurol.2005.08.017","volume":"34","author":"AS Golden","year":"2006","unstructured":"Golden AS, Haut SR, Moshe SL (2006) Nonepileptic uses of antiepileptic drugs in children and adolescents. Pediatr Neurol 34:421\u2013432","journal-title":"Pediatr Neurol"},{"key":"2092_CR27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/14737175.9.1.55","volume":"9","author":"L Citrome","year":"2009","unstructured":"Citrome L (2009) Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother 9:55\u201371","journal-title":"Expert Rev Neurother"},{"key":"2092_CR28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00228-011-1097-1","volume":"68","author":"J Mason","year":"2012","unstructured":"Mason J, Pirmohamed M, Nunn T (2012) Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 68:21\u201328","journal-title":"Eur J Clin Pharmacol"},{"key":"2092_CR29","first-page":"1113","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, Nurmikko T (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol Off J Eur Fed Neurol Soc 17:1113\u20131188","journal-title":"Eur J Neurol Off J Eur Fed Neurol Soc"},{"key":"2092_CR30","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.clinthera.2010.07.014","volume":"32","author":"C Perez","year":"2010","unstructured":"Perez C, Navarro A, Saldana MT, Masramon X, Rejas J (2010) Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study. Clin Ther 32:1357\u20131370","journal-title":"Clin Ther"},{"key":"2092_CR31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.4045\/tidsskr.11.0292","volume":"131","author":"CJ Landmark","year":"2011","unstructured":"Landmark CJ, Larsson PG, Rytter E, Johannessen SI (2011) Clarification about pregabalin and the Norwegian Prescription Database. Tidsskr Nor Laegeforen 131:800\u2013801 [Norwegian]","journal-title":"Tidsskr Nor Laegeforen"},{"key":"2092_CR32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00228-010-0920-4","volume":"67","author":"O Caster","year":"2011","unstructured":"Caster O, Edwards IR, Noren GN, Lindquist M (2011) Earlier discovery of pregabalin\u2019s dependence potential might have been possible. Eur J Clin Pharmacol 67:319\u2013320","journal-title":"Eur J Clin Pharmacol"},{"key":"2092_CR33","unstructured":"Gabapentin and pregabalin: abuse and addiction. Prescrire Int 2012; 21: 152\u20134."},{"key":"2092_CR34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.pra.0000358318.73684.df","volume":"15","author":"SP Kruszewski","year":"2009","unstructured":"Kruszewski SP, Paczynski RP, Kahn DA (2009) Gabapentin-induced delirium and dependence. J Psychiatr Pract 15:314\u2013319","journal-title":"J Psychiatr Pract"},{"key":"2092_CR35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","volume":"40","author":"BE Gidal","year":"2000","unstructured":"Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN (2000) Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 40:123\u2013127","journal-title":"Epilepsy Res"},{"key":"2092_CR36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.seizure.2015.02.017","volume":"28","author":"C Johannessen Landmark","year":"2015","unstructured":"Johannessen Landmark C, Beiske G, Baftiu A, Burns ML, Johannessen SI (2015) Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure 28:88\u201391","journal-title":"Seizure"},{"key":"2092_CR37","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E (2008) Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239\u20131276","journal-title":"Epilepsia"},{"key":"2092_CR38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/epi.12109","volume":"54","author":"T Tomson","year":"2013","unstructured":"Tomson T, Landmark CJ, Battino D (2013) Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 54:405\u2013414","journal-title":"Epilepsia"},{"key":"2092_CR39","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1111\/epi.13210","volume":"56","author":"A Baftiu","year":"2015","unstructured":"Baftiu A, Johannessen Landmark C, Nikaj V, Neslein IL, Johannessen SI, Perucca E (2015) Availability of antiepileptic drugs across Europe. Epilepsia 56:e191\u2013e197","journal-title":"Epilepsia"},{"key":"2092_CR40","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1528-1167.2007.01128.x","volume":"48","author":"E Saetre","year":"2007","unstructured":"Saetre E, Perucca E, Isojarvi J, Gjerstad L (2007) An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 48:1292\u20131302","journal-title":"Epilepsia"},{"key":"2092_CR41","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/epi.12926","volume":"56","author":"KJ Werhahn","year":"2015","unstructured":"Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert-Schmitz M, Kniess T, Schmitz B, Bernedo V, Ruckes C, Ehrlich A, Kramer G (2015) A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 56:450\u2013459","journal-title":"Epilepsia"},{"key":"2092_CR42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.seizure.2007.01.004","volume":"16","author":"S Chung","year":"2007","unstructured":"Chung S, Wang N, Hank N (2007) Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 16:296\u2013304","journal-title":"Seizure"},{"key":"2092_CR43","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/epi.12557","volume":"55","author":"MC Groot de","year":"2014","unstructured":"de Groot MC, Schuerch M, de Vries F, Hesse U, Oliva B, Gil M, Huerta C, Requena G, de Abajo F, Afonso AS, Souverein PC, Alvarez Y, Slattery J, Rottenkolber M, Schmiedl S, Van Dijk L, Schlienger RG, Reynolds R, Klungel OH (2014) Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparison. Epilepsia 55:666\u2013673","journal-title":"Epilepsia"},{"key":"2092_CR44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.yebeh.2015.11.021","volume":"55","author":"G Giussani","year":"2016","unstructured":"Giussani G, Canelli V, Bianchi E, Franchi C, Nobili A, Erba G, Beghi E (2016) A population-based study of active and drug-resistant epilepsies in Northern Italy. Epilepsy Behav: EnB 55:30\u201337","journal-title":"Epilepsy Behav: EnB"},{"key":"2092_CR45","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/pds.3457","volume":"22","author":"B Wettermark","year":"2013","unstructured":"Wettermark B, Zoega H, Furu K, Korhonen M, Hallas J, Norgaard M, Almarsdottir A, Andersen M, Andersson Sundell K, Bergman U, Helin-Salmivaara A, Hoffmann M, Kieler H, Martikainen J, Mortensen M, Petzold M, Wallach-Kildemoes H, Wallin C, S\u00f8rensen H (2013) The Nordic prescription databases as a resource for pharmacoepidemiological research\u2014a literature review. Pharmacoepidemiol Drug Saf 22:691\u2013699","journal-title":"Pharmacoepidemiol Drug Saf"}],"updated-by":[{"DOI":"10.1007\/s00228-017-2252-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T00:00:00Z","timestamp":1491523200000}}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2092-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2092-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2092-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:22:00Z","timestamp":1498314120000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2092-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["2092"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2092-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00228-017-2252-0","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]}}}